EP3732204 - ANTI-RENALASE ANTIBODIES FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 03.11.2023 Database last updated on 29.10.2024 | |
Former | Request for examination was made Status updated on 02.10.2020 | ||
Former | The international publication has been made Status updated on 06.07.2019 | Most recent event Tooltip | 06.05.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states Yale University Two Whitney Avenue New Haven CT 06510 / US | [2020/45] | Inventor(s) | 01 /
DESIR, Gary 11 Zak Hill Drive Woodbridge, CT 06525 / US | 02 /
NELSON, Bryce 23 Anderson Avenue West Haven, CT 06516 / US | [2020/45] | Representative(s) | Leonard, Thomas Charles, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2020/45] | Application number, filing date | 18897086.7 | 27.12.2018 | [2020/45] | WO2018US67611 | Priority number, date | US201762611609P | 29.12.2017 Original published format: US 201762611609 P | [2020/45] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019133667 | Date: | 04.07.2019 | Language: | EN | [2019/27] | Type: | A1 Application with search report | No.: | EP3732204 | Date: | 04.11.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.07.2019 takes the place of the publication of the European patent application. | [2020/45] | Search report(s) | International search report - published on: | US | 04.07.2019 | (Supplementary) European search report - dispatched on: | EP | 20.12.2021 | Classification | IPC: | C07K16/40, C07K16/30, C07K16/18, A61P35/00, A61K39/00, G01N33/574 | [2021/42] | CPC: |
C07K16/40 (EP,CN,US);
A61K47/6801 (CN);
A61K47/6865 (CN);
A61K47/6871 (CN);
A61P1/16 (CN);
A61P1/18 (CN);
A61P13/12 (CN);
A61P35/00 (EP,CN);
A61P9/00 (CN);
C07K16/30 (EP);
C07K16/3053 (CN);
G01N33/5743 (EP,US);
G01N33/57438 (EP);
A61K2039/505 (EP,CN);
C07K2317/24 (EP,US);
C07K2317/33 (EP);
C07K2317/34 (EP);
C07K2317/55 (EP);
C07K2317/56 (CN);
C07K2317/565 (EP,CN,US);
C07K2317/73 (EP);
C07K2317/92 (EP,CN,US);
G01N2800/067 (EP);
G01N2800/08 (EP);
|
Former IPC [2020/45] | C07K16/40, C07K16/30, C07K16/18 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/45] | Title | German: | ANTI-RENALASE-ANTIKÖRPER ZUR BEHANDLUNG UND VORBEUGUNG VON KRANKHEITEN UND STÖRUNGEN | [2020/45] | English: | ANTI-RENALASE ANTIBODIES FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS | [2020/45] | French: | ANTICORPS ANTI-RÉNALASE POUR LE TRAITEMENT ET LA PRÉVENTION DE MALADIES ET DE TROUBLES | [2020/45] | Entry into regional phase | 03.07.2020 | National basic fee paid | 03.07.2020 | Search fee paid | 03.07.2020 | Designation fee(s) paid | 03.07.2020 | Examination fee paid | Examination procedure | 03.07.2020 | Examination requested [2020/45] | 22.07.2022 | Amendment by applicant (claims and/or description) | 03.11.2023 | Despatch of a communication from the examining division (Time limit: M06) | 03.05.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 28.12.2020 | Renewal fee patent year 03 | 27.12.2021 | Renewal fee patent year 04 | 27.12.2022 | Renewal fee patent year 05 | 27.12.2023 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO2015200790 (UNIV YALE [US]); | International search | [X]US2017226228 (DESIR GARY [US], et al); |